Antibody testing to predict SARS-CoV-2 risk in immunocompromised people DOI
C.J. Duncan

The Lancet, Journal Year: 2025, Volume and Issue: 405(10475), P. 276 - 278

Published: Jan. 1, 2025

Language: Английский

Impact of SARS-CoV-2 spike antibody positivity on infection and hospitalisation rates in immunosuppressed populations during the omicron period: the MELODY study DOI Creative Commons

Lisa Mumford,

Rachel Hogg, Adam J. Taylor

et al.

The Lancet, Journal Year: 2025, Volume and Issue: 405(10475), P. 314 - 328

Published: Jan. 1, 2025

Language: Английский

Citations

1
Severe COVID-19 Pneumonia, Opportunistic Candida krusei Infection, and Acute Respiratory Distress Syndrome with Pulmonary Arterial Hypertension Treated with Bosentan: A Case Report DOI Creative Commons
Killen H. Briones‐Claudett,

Killen H. Briones-Zamora,

Jaime Galo Benites Solis

et al.

American Journal of Case Reports, Journal Year: 2025, Volume and Issue: 26

Published: Jan. 22, 2025

Background:Despite global vaccination efforts, COVID-19 still necessitates effective treatments for severe cases that can quickly escalate to life-threatening complications, such as acute respiratory distress syndrome (ARDS) and secondary pulmonary arterial hypertension (PAH).Here, we present the clinical journey of a 73-year-old Ecuadorian man who developed pneumonia complicated by an opportunistic Candida krusei infection ARDS, subsequently progressing long-term PAH, managed with bosentan, endothelin 1 (ET-1) antagonist. Case Report:The patient, vaccinated 2 doses CoronaVac, experienced including ARDS further C. infection.Despite prompt mechanical ventilation intensive care, his condition rapidly deteriorated.Clinical evaluation confirmed COVID-19-associated through bronchoalveolar lavage.The therapeutic approach combined bosentan (125 mg twice daily) dual antifungal therapy, leading significant stabilization eventual discharge.Post-discharge assessments showed persistent cardiopulmonary dysfunction, consistent post-COVID-19 syndrome. Conclusions:This case highlights critical complications in patient.While may provide substantial protection, treated corticosteroids increase risk infections like krusei, lead fibrosis PAH.This underscores need research on strategies complex emphasizes comprehensive, personalized care managing sequelae.

Language: Английский

Citations

0
Antibody testing to predict SARS-CoV-2 risk in immunocompromised people DOI
C.J. Duncan

The Lancet, Journal Year: 2025, Volume and Issue: 405(10475), P. 276 - 278

Published: Jan. 1, 2025

Language: Английский

Citations

0